The QMN Weekly Bulletin
Sept. 9, 2011
| Vol.
3 No.
36
BBC Biochemical lacks procedures and controls to prevent microbiological contamination of product, according to an FDA Form 483 recently handed to the contract manufacturer.
The FDA is considering requiring quality agreements between medical product manufacturers and their suppliers as part of its push for tighter control of the supply chain, an FDA consumer safety officer says.
AngioDynamics failed to report a field correction and the possibility that one of its devices may have figured in a death or serious injury, the FDA said in a May 27 warning letter posted online Tuesday.
Drug maker Dendreon said it would lay off 500 employees — about one-fourth of its work force — to cut costs in response to lower-than-expected sales of its new prostate-cancer treatment Provenge.
Praxair India plans to construct a new state-of-the-art air separation plant in the rapidly growing Pune-Mumbai industrial corridor of western India.
Nectar Lifesciences received U.S. Food and Drug Administration approval for its Active Pharmaceutical Ingredients manufacturing plant Unit-II in Dera Bassi, Punjab.
Berlin Pharmaceutical and Acino Pharma AG signed a long term partnership agreement under which Berlin will market a wide range of the Swiss company’s current and future products in Thailand.
A recent Food and Drug Administration report has some worrying about shortages of cancer drugs and other essential medicines.
A new production technique has been developed by the Bradford university researchers to make co-crystals for use in the pharmaceutical industry.
|
Register Now
Archives
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews
All rights reserved. Do not duplicate or redistribute in any form.